A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro

Objectives Mycobacterium tuberculosis can exist in different states in vitro, which can be denoted as fast multiplying, slow multiplying and non-multiplying. Characterizing the natural growth of M. tuberculosis could provide a framework for accurate characterization of drug effects on the different bacterial states. Methods The natural growth data of M. tuberculosis H37Rv used in this study consisted of viability defined as cfu versus time based on data from an in vitro hypoxia system. External validation of the natural growth model was conducted using data representing the rate of incorporation of radiolabelled methionine into proteins by the bacteria. Rifampicin time–kill curves from log-phase (0.25–16 mg/L) and stationary-phase (0.5–64 mg/L) cultures were used to assess the model's ability to describe drug effects by evaluating different linear and non-linear exposure–response relationships. Results The final pharmacometric model consisted of a three-compartment differential equation system representing fast-, slow- and non-multiplying bacteria. Model predictions correlated well with the external data (R2 = 0.98). The rifampicin effects on log-phase and stationary-phase cultures were separately and simultaneously described by including the drug effect on the different bacterial states. The predicted reduction in log10 cfu after 14 days and at 0.5 mg/L was 2.2 and 0.8 in the log-phase and stationary-phase systems, respectively. Conclusions The model provides predictions of the change in bacterial numbers for the different bacterial states with and without drug effect and could thus be used as a framework for studying anti-tubercular drug effects in vitro.

[1]  Yanmin Hu,et al.  Targeting non-multiplying organisms as a way to develop novel antimicrobials. , 2008, Trends in pharmacological sciences.

[2]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[3]  D. Mitchison,et al.  Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[4]  M. Rajandream,et al.  Regulation of hmp Gene Transcription inMycobacterium tuberculosis: Effects of Oxygen Limitation and Nitrosative and Oxidative Stress , 1999, Journal of bacteriology.

[5]  C. Senner,et al.  Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum , 2008, PLoS medicine.

[6]  D. Kell,et al.  Formation and resuscitation of "non-culturable" cells of Rhodococcus rhodochrous and Mycobacterium tuberculosis in prolonged stationary phase. , 2002, Microbiology.

[7]  Andrew C. Hooker,et al.  Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.

[8]  A. Diacon,et al.  The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. , 2015, The Journal of antimicrobial chemotherapy.

[9]  R. Bax,et al.  The future challenges facing the development of new antimicrobial drugs , 2002, Nature Reviews Drug Discovery.

[10]  A. Lesse,et al.  Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia , 2009, Antimicrobial Agents and Chemotherapy.

[11]  Stuart L. Beal,et al.  Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  P. Butcher,et al.  Detection of mRNA Transcripts and Active Transcription in Persistent Mycobacterium tuberculosisInduced by Exposure to Rifampin or Pyrazinamide , 2000, Journal of bacteriology.

[13]  L. G. Wayne Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions. , 2015, The American review of respiratory disease.

[14]  B. Ngasala,et al.  Population Pharmacokinetics and Pharmacodynamics of Artemether and Lumefantrine during Combination Treatment in Children with Uncomplicated Falciparum Malaria in Tanzania , 2010, Antimicrobial Agents and Chemotherapy.

[15]  D B Kell,et al.  A bacterial cytokine. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Vinks,et al.  Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion , 1997, Antimicrobial agents and chemotherapy.

[17]  S. Gillespie,et al.  A reiterative method for calculating the early bactericidal activity of antituberculosis drugs. , 2002, American journal of respiratory and critical care medicine.

[18]  Mats O. Karlsson,et al.  Handling Data Below the Limit of Quantification in Mixed Effect Models , 2009, The AAPS Journal.

[19]  Yanmin Hu,et al.  New Strategies for Antibacterial Drug Design , 2006 .

[20]  Mats O. Karlsson,et al.  Semimechanistic Pharmacokinetic/Pharmacodynamic Model for Assessment of Activity of Antibacterial Agents from Time-Kill Curve Experiments , 2006, Antimicrobial Agents and Chemotherapy.

[21]  G. Maartens,et al.  A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture , 2012, Antimicrobial Agents and Chemotherapy.

[22]  Michael Nikolaou,et al.  Modelling time-kill studies to discern the pharmacodynamics of meropenem. , 2005, The Journal of antimicrobial chemotherapy.

[23]  R J Keizer,et al.  Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose , 2013, CPT: pharmacometrics & systems pharmacology.

[24]  L. G. Wayne Dormancy ofMycobacterium tuberculosis and latency of disease , 1994, European Journal of Clinical Microbiology and Infectious Diseases.

[25]  Arseny S Kaprelyants,et al.  Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification. , 2011, Tuberculosis.

[26]  O. Cars,et al.  A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants. , 2015, The Journal of antimicrobial chemotherapy.

[27]  Lena E. Friberg,et al.  Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization , 2011, Antimicrobial Agents and Chemotherapy.

[28]  M. Barer,et al.  Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. , 2010, American journal of respiratory and critical care medicine.

[29]  S. Bhavnani,et al.  Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. , 2011, Diagnostic microbiology and infectious disease.

[30]  Ss Beal,et al.  NONMEM User’s Guides. (1989–2009) , 2009 .

[31]  A. Coates,et al.  New strategies for antibacterial drug design: targeting non-multiplying latent bacteria. , 2006, Drugs in R&D.

[32]  L. Gabbasova,et al.  Global tuberculosis report (2014) , 2014 .

[33]  M. Karlsson,et al.  Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria , 2002, European Journal of Clinical Pharmacology.

[34]  D. Mitchison,et al.  Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.

[35]  O. Cars,et al.  A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. , 2014, The Journal of antimicrobial chemotherapy.

[36]  L. Wayne,et al.  Synchronized replication of Mycobacterium tuberculosis , 1977, Infection and immunity.

[37]  Neang S. Ly,et al.  Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.

[38]  Steven G. Woolfrey,et al.  Analysis of Toxicokinetic Data Using NONMEM: Impact of Quantification Limit and Replacement Strategies for Censored Data , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[39]  D. Mitchison,et al.  High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo , 2015, Front. Microbiol..

[40]  Mats O. Karlsson,et al.  Impact of Omission or Replacement of Data Below the Limit of Quantification on Parameter Estimates in a Two-Compartment Model , 2002, Pharmaceutical Research.

[41]  Hairong Huang,et al.  Rifampin Stability in 7H9 Broth and Löwenstein-Jensen Medium , 2010, Journal of Clinical Microbiology.

[42]  P. Butcher,et al.  Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. , 1998, FEMS microbiology letters.

[43]  L. Aarons,et al.  Use of Nonlinear Mixed-Effects Analysis for Improved Precision of Early Pharmacodynamic Measures in Tuberculosis Treatment , 2006, Antimicrobial Agents and Chemotherapy.

[44]  Michael Young,et al.  Mutants of Mycobacterium tuberculosis Lacking Three of the Five rpf-Like Genes Are Defective for Growth In Vivo and for Resuscitation In Vitro , 2005, Infection and Immunity.

[45]  G. Kaplan,et al.  The resuscitation-promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro , 2007, Molecular microbiology.

[46]  D. Mitchison,et al.  Persister populations of Mycobacterium tuberculosis in sputum that grow in liquid but not on solid culture media. , 2014, The Journal of antimicrobial chemotherapy.

[47]  P. Andrew,et al.  The in vivo environment accelerates generation of resuscitation-promoting factor-dependent mycobacteria. , 2014, American journal of respiratory and critical care medicine.